Valuation : Supernus Pharmaceuticals, Inc.

Market Cap 2.61B 2.24B 2.1B 1.92B 3.62B 249B 3.64B 24.87B 9.64B 126B 9.8B 9.58B 416B P/E 2026 *
-224x
P/E 2027 * 36.6x
Enterprise Value 2.61B 2.24B 2.1B 1.92B 3.62B 249B 3.64B 24.87B 9.64B 126B 9.8B 9.58B 416B EV / Sales 2026 *
2.95x
EV / Sales 2027 * 1.9x
Free-Float
95.51%
Yield 2026 *
-
Yield 2027 * -
1 day-1.06%
1 week-7.54%
Current month+0.56%
1 month-2.86%
3 months-6.05%
6 months-19.50%
Current year-9.70%
1 week 44.22
Extreme 44.225
47.82
1 month 42.62
Extreme 42.625
52.5
Current year 42.45
Extreme 42.45
59.68
1 year 42.45
Extreme 42.45
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 22/12/2005
Director of Finance/CFO 67 23/08/2021
Compliance Officer 63 01/01/2012
Director TitleAgeSince
Director/Board Member 64 22/12/2005
Chairman 81 10/08/2016
Director/Board Member 80 16/11/2010
Date Insider Type Main position Quantity % Market Cap.
12/08/26 Fiscal year

Chief Technology Officer

4,097 0.0073%
12/08/26 Fiscal year

Chief Financial Officer

3,104 0.0055%
12/08/26 Fiscal year

Founder

72,340 0.1290%
Change 5-day change 1-year change 3-year change Capi.($)
-1.06%-7.54%+1.26%+42.98% 2.61B
-2.14%+0.59%+80.14%+38.92% 378B
-0.72%+0.22%+27.98%-14.65% 70.23B
-2.07%-0.52%+46.80%+150.78% 12.15B
+1.75%+1.10%+2.03%-0.63% 8.45B
-2.31%-0.94%-16.02%-0.35% 5.17B
-1.19%+4.65%-28.68%+15.69% 4.66B
+1.34%-11.74%-32.42%+8.76% 3.03B
+2.75%-4.05%-15.05%-3.95% 2.13B
-0.68%+1.85%+258.65%+1,185.83% 1.79B
Average -0.43%-0.76%+32.47%+142.34% 48.8B
Weighted average by Cap. -1.80%+0.43%+67.51%+36.52%

Financials

2026 *2027 *
Net sales 886M 760M 714M 652M 1.23B 84.49B 1.24B 8.44B 3.27B 42.62B 3.33B 3.25B 141B 1.37B 1.18B 1.1B 1.01B 1.9B 131B 1.91B 13.08B 5.07B 66B 5.15B 5.04B 219B
Net income -11.54M -9.91M -9.3M -8.49M -16.03M -1.1B -16.11M -110M -42.65M -555M -43.34M -42.4M -1.84B 71.54M 61.4M 57.63M 52.64M 99.34M 6.82B 99.82M 682M 264M 3.44B 269M 263M 11.4B
Net Debt - -
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
26/08/26 $44.88 -1.06% 499,684
25/08/26 $45.36 +0.55% 496,056
24/08/26 $45.11 -1.61% 495,505
21/08/26 $45.85 -3.37% 748,894
20/08/26 $47.45 -2.25% 646,851
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
44.88USD
Average target price
61.75USD
Spread / Average Target
+37.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SUPN Stock